NEW DELHI : Brinton Pharmaceuticals has got the approval of the Drugs Controller General of India (DCGI) for marketing favipiravir under the brand name Faviton for the management of mild to moderate covid-19 patients, the company said on Thursday.The emerging favourable global clinical evidence suggests that favipiravir is an effective treatment option in the management of mild to moderate covid-19, said company officials.
This medication is administered orally and thus is more convenient than intravenously administered medicines.In India, favipiravir was first approved by the regulatory authorities in June under emergency use authorization to treat covid-19 patients, the company said.Faviton will be available in 200mg tablets and will also.